These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
296 related items for PubMed ID: 12745273
1. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R. Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273 [Abstract] [Full Text] [Related]
2. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R. Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170 [Abstract] [Full Text] [Related]
4. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Schweizer C, Reu FJ, Ho AD, Hensel M. Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529 [Abstract] [Full Text] [Related]
5. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943 [Abstract] [Full Text] [Related]
6. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482 [Abstract] [Full Text] [Related]
7. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147 [Abstract] [Full Text] [Related]
8. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962 [Abstract] [Full Text] [Related]
9. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH. Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292 [Abstract] [Full Text] [Related]
10. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Zhou Z, Yang R. Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784 [Abstract] [Full Text] [Related]
11. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R. Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702 [Abstract] [Full Text] [Related]
12. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foà R. Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410 [Abstract] [Full Text] [Related]
13. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP. J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113 [Abstract] [Full Text] [Related]
15. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. J Immunother; 2001 Apr; 24(3):272-9. PubMed ID: 11394506 [Abstract] [Full Text] [Related]
16. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980 [Abstract] [Full Text] [Related]
17. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R. Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115 [Abstract] [Full Text] [Related]
18. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus. Lee SY, Hsu PY, Juan KC, Chang H, Huang WH, Lai PC. Int Immunopharmacol; 2010 May; 10(5):632-4. PubMed ID: 20172055 [Abstract] [Full Text] [Related]
19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ. Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [Abstract] [Full Text] [Related]
20. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Popa C, Leandro MJ, Cambridge G, Edwards JC. Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244 [Abstract] [Full Text] [Related] Page: [Next] [New Search]